Keryx Biopharmaceuticals (NASDAQ:KERX)

biotech

Keryx is another biotech which has struggled recently despite an absence of negative developments specific to the company. The company has already reported positive phase III efficacy data for kidney failure drug Zerenex and is only awaiting results of a phase III safety trial in June 2012 before proceeding with an NDA. Meanwhile, phase III efficacy data for anti-neoplastic agent perifosine in colorectal cancer may be available as early as Q4 2011, although I suspect that timeframe may be pushed back. The trial recently passed the final interim futility analysis. Like all speculative stocks, Keryx could potentially drop much further in a broad decline but is definitely one to watch for a rebound.

I cannot resist the potential, so I am parking my money in a good basket of small cap biotech picks. This is the sector to be in for the next 5 years in a big, big way. Only picking the stocks in this sector with the brightest potential.

I am an investor of Kerx for along time. I am hinting this is a must deal for them. Good news today but like
having babies, we must wait it out.

Working in research related to Kidney problems, this stock is speculative but has the potential to be a genuine gamechanger. Besides the natural vulnerabilities of aging, the kidneys seem to be the "organ of choice for every counterindication" in pharma world, that is, so many treatments for so many conditions will [for a small but significant number of patients], threaten kidney functions. Finally, KERX is "affordable" for a wellmoneyed larger company like Pfizer looking to pickup a few quick new patents.

Phase 3 trials will show if this "lottery ticket" has what is takes to become a 10 bagger, I believe so.

See Aezs - This company has exclusive rights to market a cancer drug that is now in stage III trials. If successful, both companies should soar !

Perifosine a novel oral anti-cancer compound, showing promising clinical activity. The SPA status on their pipeline is encouraging. Also, they recently did a secondary offering of about 7mil shares @ $4.70 that finished may 9 2011 and more coverage has been given by analyst, always a good thing. I'm long kerx and have been for about a year. Highly recommend purchasing shares on unwanted pullbacks/corrections.

They have a nice looking pipeline with some pretty good look potential. I think it is a bit on the risky side but, with great risk comes great reward.

Anything to do with the diabetic epidemic should perform well, as long as management does their job and stays focussed.

good management important product

I´ve already commented on perfosine and some important dates that one should have in mind in my previous pitch on Aeterna Zentaris. Regarding Zenerex, another of Keryx's lead compounds, it's still two years to arrive to the phase III trial completion and a subsequent NDA filing. After presenting positive top-line results of its short term trial, Keryx will probably be subject to the typical ups and downs amid some PR releases and things like that. With no major catalysts until 2012, I would wait for a decrease on the price to press the "buy" button.

Will become profitable eventually.

Several meds in final stages due to be approved by fda

If the drugs in level three get approved by the FDA, KERX will do quit well in the short-term.

lots on the pipeline.positive data for perifosine and zeranex fda approval

Your typical powder-keg biotech. Total spec play, but the upside is ridiculous and there will likely be anticipatory run-up. Might go lower first, but this is a wildcard in the short term and long term upside vastly outweighs short term risk.

They have made a nice run up to 4 dollars in the last few days with no news.....yet
They are partners with aezs on a phase 3 cancer drug that looks very promising, plus all their own meeds in the pipeline.
This is at least an $8 stock by years end.

This is a solid small market stock with some promising drugs in their pipeline. Perifosine will be the drug that once approved will lift this companys revenue and bring the stock price back to where it was 5 years ago.